



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2016/10/14
(87) Date publication PCT/PCT Publication Date: 2017/04/20
(85) Entrée phase nationale/National Entry: 2018/04/24
(86) N° demande PCT/PCT Application No.: EP 2016/074817
(87) N° publication PCT/PCT Publication No.: 2017/064311
(30) Priorité/Priority: 2015/10/16 (GB1518348.6)

(51) Cl.Int./Int.Cl. *A61K 38/44* (2006.01),
A61P 31/04 (2006.01)
(71) Demandeur/Applicant:
SYSTAGENIX WOUND MANAGEMENT, LIMITED, GB
(72) Inventeurs/Inventors:
BOURDILLON, KATIE, GB;
WESTMORELAND, MATTHEW, GB;
REGAN, SOPHIE, GB
(74) Agent: BORDEN LADNER GERVAIS LLP

(54) Titre : COMPOSITION COMPRENANT UNE ENZYME OXYDOREDUCTASE ET SON UTILISATION
ANTIBACTERIENNE
(54) Title: COMPOSITION COMPRISING AN OXIDOREDUCTASE ENZYME AND ITS ANTIBACTERIAL USE

(57) Abrégé/Abstract:

A composition comprising an oxidoreductase enzyme and a substrate for the enzyme for use in treating or preventing biofilm formation by a population of pathogenic bacteria. The composition can be incorporated into a wound dressing for use in promoting wound healing.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(10) International Publication Number

WO 2017/064311 A1

(43) International Publication Date
20 April 2017 (20.04.2017)

(51) International Patent Classification:
A61K 38/44 (2006.01) A61P 31/04 (2006.01)

(21) International Application Number:
PCT/EP2016/074817

(22) International Filing Date:
14 October 2016 (14.10.2016)

(25) Filing Language:
English

(26) Publication Language:
English

(30) Priority Data:
1518348.6 16 October 2015 (16.10.2015) GB

(71) Applicant: SYSTAGENIX WOUND MANAGEMENT IP CO. BV. [NL/NL]; Keizersgracht 64, 1015 Amsterdam (NL).

(72) Inventors: BOURDILLON, Katie; C/O Systagenix, Gargrave Yorkshire BD23 3RX (GB). WESTMORELAND, Matthew; C/O Systagenix, Gargrave Yorkshire BD23 3RX (GB). REGAN, Sophie; C/O Systagenix, Gargrave Yorkshire BD23 3RX (GB).

(74) Agent: HOLLYWOOD, Jane; Olswang LLP, 90 High Holborn, London Greater London WC1V 6XX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2017/064311 A1

(54) Title: COMPOSITION COMPRISING AN OXIDOREDUCTASE ENZYME AND ITS ANTIBACTERIAL USE

(57) Abstract: A composition comprising an oxidoreductase enzyme and a substrate for the enzyme for use in treating or preventing biofilm formation by a population of pathogenic bacteria. The composition can be incorporated into a wound dressing for use in promoting wound healing.

COMPOSITION COMPRISING AN OXIDOREDUCTASE ENZYME AND ITS ANTIBACTERIAL USE

The present invention relates to compositions useful in the treatment of pathogenic bacterial biofilms.

5 Biofilms are collections of microorganisms which adhere to surfaces, surrounding themselves with secreted polymers and forming three dimensional microbial communities with coordinated multi-cellular behaviour. The ability of bacteria to form these complex communities is believed to impede activity of host defences and treatments against pathogens, with biofilm populations often displaying a tolerance to 10 antimicrobial treatment.

Bacterial biofilms are known to be associated with a variety of medical conditions including dental caries, *Pseudomonas* infection in the lungs of cystic fibrosis patients and endocarditis due to biofilms growing on artificial heart valves. Increasing evidence 15 indicates that biofilms may also contribute to delayed wound healing, particularly in chronic wounds.

It has been estimated that 60-80 percent of microbial infections in the body are caused by bacteria growing as a biofilm, as opposed to free-floating bacteria.

20 Biofilms can grow on most surfaces including wounds and are thought to induce inflammation and therefore delay wound healing.

It is well established that a composition which has demonstrated antimicrobial efficacy against vegetative bacteria is often not also effective against biofilms formed by the same bacteria. This is true for both antibiotics and broad spectrum antiseptics such as silver, iodine and honey (Saginur *et al.* 2006; *Antimicrob Agents and Chemother* 50(1) 25 55-61).

There is a continued requirement for effective treatments of pathogenic bacterial biofilms.

30 Compositions comprising an oxidoreductase enzyme and a substrate for the enzyme, and methods or uses involving such compositions, are described herein. A composition comprising an oxidoreductase enzyme and a substrate for the enzyme may be used to treat or prevent biofilm formation by a population of pathogenic bacteria, e.g., to reduce

or reverse formation of a pathogenic bacterial biofilm on a surface, or to remove a pathogenic bacterial biofilm from a surface. Accordingly, methods of treating or preventing biofilm formation by administration or application of such a composition, are described. Use of the compositions may be antiseptic, to treat or prevent biofilm formation in or on a patient (e.g., at the site of a wound) or disinfectant, to treat or prevent biofilm formation in or on an inanimate object (e.g., on a medical device).

In one aspect, a composition comprising an oxidoreductase enzyme and a substrate for the enzyme for use in treating or preventing biofilm formation by a population of pathogenic bacteria in or on a patient is disclosed.

10 Biofilm formation includes establishment of a biofilm and/or biofilm-like growth.

The composition comprises a therapeutically effective amount of the enzyme and substrate for treating or preventing biofilm formation.

In one embodiment, the composition does not comprise lactoperoxidase.

15 The composition can consist of an oxidoreductase enzyme, a substrate for the enzyme and a pharmaceutically acceptable carrier.

In use, the composition can be hydrated, for example by wound exudate, and this assists the process of the enzyme metabolising the enzyme substrate to produce hydrogen peroxide. For example, glucose oxidase metabolises glucose producing hydrogen peroxide.

20 Usually the methods and uses described herein will comprise applying or administering both the enzyme and its substrate. However, where an appropriate substrate for the enzyme is present or expected to be present at the site to be treated, the enzyme may be applied or administered alone, where it may combine with its substrate at the application site or surface being treated.

25 The composition treats biofilm formation by causing a reduction in biofilm formation which would be considered a statistically significant reduction relative to untreated biofilm by a skilled person. A significant reduction is a 1-reduction in biofilm total viable count of at least 1 \log_{10} unit. The reduction in biofilm formation could also be a 1-reduction in biofilm total viable count of at least 2, at least 3, at least 4 or at least 5
30 \log_{10} units.

In a preferred embodiment, the oxidoreductase enzyme is glucose oxidase and the substrate is glucose. The glucose can be provided as honey. The glucose content of the honey can be over 20g per 100g, including 25g-40g per 100g.

In a further preferred embodiment, the oxidoreductase enzyme is fructose oxidase and the substrate is fructose. In a further preferred embodiment, the oxidoreductase enzyme is hexose oxidase and the substrate is a hexose sugar. In a further preferred embodiment, the oxidoreductase enzyme is cholesterol oxidase and the substrate is cholesterol. In a further preferred embodiment, the oxidoreductase enzyme is galactose oxidase and the substrate is galactose. In a further preferred embodiment, the oxidoreductase enzyme is pyranose oxidase and the substrate is pyranose. In a further preferred embodiment, the oxidoreductase enzyme is choline oxidase and the substrate is choline. In a further preferred embodiment, the oxidoreductase enzyme is pyruvate oxidase and the substrate is pyruvate. In a further preferred embodiment, the oxidoreductase enzyme is glycollate oxidase and the substrate is glycollate.

15 A mixture of oxidoreductase enzymes and their corresponding substrates can also be used. For example, glucose oxidase, glucose, fructose oxidase and fructose can be used.

The composition can be a substantially neutral pH.

In a further embodiment, the pH can be 4.5-6.5, including pH 4.5 to 5.5.

20 The composition can be combined with other antibacterial treatments, such as ionic silver, iodine, antibiotics, Prontosan®, PHMB, chlorhexidine, copper or surfactants, or active components that promote healing (such as oxidised regenerated cellulose, antioxidants or anti-inflammatories).

The oxidoreductase enzyme can be used at a concentration of 0.2 U/mL- 60.0 U/mL, preferably at least 1 U/mL, at least 2 U/mL, at least 6 U/ml, at least 10 U/ml or at least 15 U/ml, including 2 U/mL – 20 U/mL.

The substrate can be used at a concentration of 10 to 85 % w/w, preferably at least 20 % w/w, including at least 30 % w/w or at least 40 % w/w.

30 The compositions can be used to treat or prevent biofilms formed by any type of pathogenic bacteria. A pathogenic bacteria is a bacteria that is infectious to humans

and/or animals. The bacteria can be a Gram-negative bacteria species or a Gram-positive bacteria species. The bacteria can be selected from the group consisting of *Pseudomonas*, *Staphylococcus*, *Streptococcus*, *Salmonella*, *Escherichia*, *Klebsiella*, *Bacillus*, *Clostridium*, *Campylobacter*, *Capnocytophaga*, *Proteus*, *Shigella*, *Bacteroides*, 5 *Prevotella*, *Fusobacterium*, *Aeromonas* and *Acinetobacter*.

In a preferred embodiment, the population of bacteria referred to herein comprises or consists of *Pseudomonas aeruginosa*. In a further preferred embodiment, the population of bacteria referred to herein comprises or consists of *Staphylococcus aureus* including methicillin resistant *S. aureus* (MRSA). In a further preferred embodiment, the 10 population of bacteria referred to herein comprises or consists of *Staphylococcus epidermidis*. In a further embodiment, the population of bacteria referred to herein comprises or consists of a combination of *Pseudomonas aeruginosa* and *Staphylococcus aureus*.

Biofilms can form on surface wounds, on medical devices, such as catheters, and on 15 external surfaces, such as hospital vents. The composition disclosed herein can be used to treat biofilms on any type of surface including these surfaces.

The composition disclosed herein can be in any form suitable for applying to one of said surfaces. In a preferred embodiment, the composition is in a form suitable for topical administration, for example, ointment, cream, gel, liquid or in a transdermal patch. 20 The compositions disclosed herein can, in addition to the substrate and enzyme, comprise or consist of one or more pharmaceutically acceptable carriers. In a preferred embodiment, the carrier is suitable for topical delivery.

The composition can be a liquid, semi-solid or solid composition for application directly to the surface of a wound, or the composition is applied to the surface of, or incorporated 25 into, a solid wound contacting layer such as a wound dressing foam, gauze or film. Preferably, the wound dressing composition is a fluid or a gel comprising from 0.2 U/mL- 60.0 U/mL enzyme and 10 to 85 % w/w substrate in combination with one or more conventional pharmaceutical carriers for topical application to a wound.

Suitable carriers include hydrogels containing cellulose derivatives, including 30 hydroxyethyl cellulose, hydroxymethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose and mixtures thereof; and hydrogels containing polyacrylic acid (carbopol), creams/ointments used for topical pharmaceutical

preparations, e.g. creams based on cetomacrogol emulsifying ointment, a thickener such as alginate, preservatives such as benzyl alcohol, buffers to control pH such as disodium hydrogen phosphate/sodium dihydrogen phosphate, agents to adjust osmolarity such as sodium chloride, purified water and stabilisers such as EDTA.

5 An embodiment disclosed herein is a composition consisting of glucose oxidase, glucose and a pharmaceutically acceptable carrier for use in treating or preventing biofilm formation in a wound by a population of pathogenic bacteria comprising *Pseudomonas aeruginosa*.

10 A further embodiment is a composition consisting of glucose oxidase, glucose and a pharmaceutically acceptable carrier for use in treating or preventing biofilm formation in a wound by a population of pathogenic bacteria comprising *Staphylococcus aureus* including methicillin resistant *S. aureus*.

15 The composition disclosed herein can be administered to the treatment area at least once a day, including twice a day. The treatment can be continued for at least a week, including at least two weeks.

A further aspect relates to a wound dressing comprising a composition disclosed herein for use in treating or preventing biofilm formation by a population of pathogenic bacteria.

20 The composition disclosed herein can be incorporated into a foam for use as a wound dressing. The wound dressing can be a hydropolymer foam mixture (for example, Tielle[®], manufactured by Systagenix), a freeze-dried composite comprising collagen and oxidised regenerated cellulose (for example, Promogran[®], manufactured by Systagenix) or a silicone dressing (for example, Adaptic Touch[®], manufactured by Systagenix).

25 The foam may be a reticulated, open-cell polyurethane or polyether foam that allows good permeability of wound fluids. One such foam material that has been used is the V.A.C.[®] GranufoamTM Dressing available from Kinetic Concepts, Inc. (KCI) of San Antonio, TX. The reticulated pores of the GranufoamTM Dressing material, that are in the range of about 400 to 600 microns. A material with a higher, or lower, density (smaller pore size) than GranufoamTM Dressing material may be desirable in some situations.

30 The foam material might also be a combination or layering of materials; for example, a first layer of hydrophilic foam might be disposed adjacent to a second layer of

hydrophobic foam to form the foam. The foam may also be a reticulated foam that is later felted to a thickness of less about half its original thickness.

The oxidoreductase enzyme and substrate can be incorporated into the wound dressing such that the enzyme and substrate are physically separated from one another. For example, this could be achieved by including the oxidoreductase enzyme in one layer of the dressing and the substrate in another. When the dressing is hydrated, for example by wound exudate, the oxidoreductase enzyme can start metabolising the substrate to produce hydrogen peroxide.

The wound dressing composition in a sheet or layer form could, for example, have an area of from about 1cm² to about 400cm², in particular from about 2cm² to about 100cm². The basis weight of the sheet is typically from about 100g/m² to about 5000g/m², for example from about 400g/m² to about 2000g/m². The sheet of the composition would form an active layer of the dressing.

15 The said active layer in the dressings would normally be the wound contacting layer in use, but in some embodiments it could be separated from the wound by a liquid-permeable top sheet. Preferably, the area of the active layer is from about 1 cm² to about 400 cm², more preferably from about 4 cm² to about 100 cm².

20 The wound dressing may consist essentially of the active layer of the composition, in which case the dressing would normally be used in conjunction with a suitable secondary dressing. In other embodiments, the wound dressing comprises a backing sheet extending over the active layer opposite to the wound facing side of the active layer. Preferably, the backing sheet is larger than the active layer such that a marginal 25 region of width 1 mm to 50 mm, preferably 5mm to 20mm extends around the active layer to form a so-called island dressing. In such cases, the backing sheet is preferably coated with a pressure sensitive medical grade adhesive in at least its marginal region.

30 Preferably, the backing sheet is substantially liquid-impermeable. The backing sheet is preferably semipermeable. That is to say, the backing sheet is preferably permeable to water vapour, but not permeable to liquid water or wound exudate. Preferably, the backing sheet is also microorganism-impermeable.

35 Suitable polymers for forming the backing sheet include polyurethanes and poly alkoxyalkyl acrylates and methacrylates such as those disclosed in GB-A-1280631.

Preferably, the backing sheet comprises a continuous layer of a high density blocked polyurethane foam that is predominantly closed-cell. The adhesive layer (where present) should be moisture vapour transmitting and/or patterned to allow passage of water vapour therethrough. The adhesive layer is preferably a continuous moisture vapour transmitting, pressure-sensitive adhesive layer of the type conventionally used for island-type wound dressings. Polyurethane-based pressure sensitive adhesives are preferred.

The wound dressing may further comprise an absorbent layer between the active layer and the backing sheet, especially if the dressing is for use on exuding wounds. The optional absorbent layer may be any of the layers conventionally used for absorbing wound fluids, serum or blood in the wound healing art, including gauzes, nonwoven fabrics, superabsorbents, hydrogels and mixtures thereof.

15 A removable cover sheet may protect the wound-facing surface of the dressing. The cover sheet is normally formed from flexible thermoplastic material. Suitable materials include polyesters and polyolefins. Preferably, the adhesive- facing surface of the cover sheet is a release surface. That is to say a surface that is only weakly adherent to the active layer and the adhesive on the backing sheet to assist removal of the cover sheet.

20 For example, the cover sheet may be formed from a non-adherent plastic such as a fluoropolymer, or it may be provided with a release coating such as a silicone or fluoropolymer release coating.

A wound dressing disclosed herein can be used to treating a wide range of wound types where biofilm formation can occur, for example, acute or chronic wounds.

25 As used herein, the term “wound” means a break in the skin. Examples of wounds include skin ulcers (e.g. bed sores, diabetic ulcers and leg ulcers), burns, surgical wounds and abrasions. Wound may be, for example, chronic, acute, traumatic, sub-acute, dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps or grafts.

30 In the case of a chronic wound, the dressing can be applied to the chronic wound for a period of at least 1 hour, at least 6 hours, and at least 12 hours. The treatment may be extended for several days, 1, 2, 3 or more weeks, with dressing changes as appropriate.

The wound can be uninfected, in which case the wound dressing prevents infection. Alternatively, the wound can be infected and the wound dressing treats or reduces the infection by treating biofilm formation.

The composition can be used in conjunction with negative pressure therapy. For 5 example, the composition can be applied directly to a wound that will also be treated with negative pressure therapy or the composition can be incorporated into a wound dressing that is to be used with a vacuum for negative pressure therapy.

The wound dressings will be packaged in sterile packaging, and sterilized using routine methods, such as by gamma-irradiation.

10 A further aspect relates to an ex vivo or in vivo method of preventing formation of, or removing, a pathogenic bacterial biofilm (that is a biofilm formed by a population of pathogenic bacteria) from a surface comprising administering a composition comprising an oxidoreductase enzyme and a substrate for the enzyme to said surface.

In an ex vivo method, the composition can be used to prevent biofilm formation on a 15 medical device, for example, by coating the medical device in part or completely with the composition prior to use of the device.

A further aspect relates to a method for the treatment or prevention of biofilm formation by a population of pathogenic bacteria, comprising administration of a therapeutic amount of a composition comprising an oxidoreductase enzyme and a substrate to a 20 patient in need thereof.

A further aspect relates to a method for the treatment or prevention of biofilm formation by a population of pathogenic bacteria, comprising administration of a therapeutic amount composition consisting of an oxidoreductase enzyme, a substrate and a pharmaceutically acceptable carrier to a patient in need thereof.

25 A further aspect relates to a method of treatment or prevention of biofilm formation by a population of pathogenic bacteria in a wound by applying a wound dressing comprising an oxidoreductase enzyme and a substrate to a wound site.

Methods may comprise identifying a wound containing a biofilm, or a wound at risk of 30 infection by biofilm-forming bacteria, and treating the wound by applying the composition of the invention to the wound.

The composition may be applied as a mixture of the oxidoreductase enzyme and substrate, or these two components may be applied separately, e.g., as two solutions. The enzyme and substrate may be administered simultaneously, optionally as a combined preparation, as separate components of a wound dressing, or as a two-part

5 solution.

Compositions of the invention may be incorporated wound dressings as described above. Thus, it may be convenient to apply the composition via a wound dressing, such as a foam or a gauze incorporating the composition. A further aspect relates to a method of manufacturing a composition as disclosed herein. The composition may be

10 manufactured by any suitable processing method. For example, the composition disclosed herein of an oxidoreductase enzyme and a substrate for the enzyme can be mixed with a pharmaceutically acceptable carrier, also as described herein.

Also contemplated is a kit comprising a composition disclosed herein. The kit can include a container comprising the composition and instructions for use of the

15 composition for treating or preventing biofilm formation. The enzyme and substrate may be provided in separate containers and/or separate solutions within the kit.

“Treating” or “preventing” a biofilm, as disclosed herein, refers to reduction or elimination of biofilm from a surface, including killing and/or inhibition of growth of microbes in the biofilm, and/or prophylactic prevention of formation of or growth of a

20 biofilm on a surface.

Treatment or prevention of bacterial biofilms may be determined experimentally as illustrated in the Examples herein. The effect of a composition on a biofilm may be determined by a method including the following steps:

- a) providing a bacterial culture;
- 25 b) inoculating a sterile disc in each of a control and a test culture well with an inoculum from the bacterial culture;
- c) adding the composition to the test culture well;
- d) incubating the test and control culture wells under conditions in which the bacteria form a biofilm; and

e) determining the number or concentration of bacteria on the discs from the test and control culture wells respectively; wherein a lower number or concentration of bacteria in the test well compared with the control well indicates that the composition is suitable for treating or preventing formation of a biofilm by the bacteria.

5 Statistical significance of any reduction may be determined. Illustrative methods for the above steps are described in the Examples.

Preferred features of the second and subsequent aspects disclosed herein are as for the first aspect *mutatis mutandis*.

Figures

10 The present invention will now be further described by way of reference to the following Example and Figures which are provided for the purposes of illustration only and are not to be construed as being limiting on the invention. Reference is made to the following Figures in which:

15 Figure 1 illustrates the effect of 24 hour honey, glucose oxidase and honey/glucose oxidase exposure against 24 hour old *P. aeruginosa* biofilms;

Figure 2 illustrates the effect of 24 hour honey, glucose oxidase and honey/glucose oxidase exposure against 24 hour old *S. aureus* biofilms.

Examples

Example 1 Biofilm Model

20 Method

Stationary phase cultures of *S. aureus* or *P. aeruginosa* grown in TSB were adjusted to 0.5 McFarland (c. 1.5×10^8 CFU/mL) and diluted a further 1:4 ratio (1 mL inoculum with 3 mL 0.1% Bactopeptone). A viable count was taken of each inoculum preparation. Sterile discs (6mm diameter x 1.0mm) housed in 24 well culture plates were inoculated 25 with 80 μ L of culture. 0.2 ml of a test media was then added, the assay plates were parafilmed and incubated for 24 h at 37 degrees Celsius with 80 rpm shaking to allow biofilm formation. Unused wells were filled with PBS to increase humidity and prevent evaporation.

After 24 hours incubation, cellulose discs/biofilms were rinsed with PBS to remove any adherent vegetative cells and transferred to 150 µl of fresh media.

For the honey (as the source of glucose) and Prontosan®, 30 µl was added to each test disc.

5 **For the glucose oxidase**, a 100U/ml stock solution was made as follows; glucose oxidase is supplied as 100,000-250,000 U/g freeze dried powder. Assuming the lowest concentration (100,000 U/g), 3.5mg (350U) was added to 3.5 ml of DPBS to give a 100U/ml working stock which was filter sterilised.

For the Pseudomonas experiment, the working stock was diluted in PBS to give a 10 U/ml solution – 30µl was added to a disc/biofilm.

For the *S. aureus* experiment, 100µl and 300µl of stock was diluted in 5ml volumes of PBS to prepare 'low' and 'high' glucose oxidase alone solutions – 30µl added to a disc/biofilm.

For the honey/glucose oxidase mixture-

15 Two honey/glucose oxidase mixtures were tested:

- A- 2U/g (2 U/ml) referred to as 'Low' – 5g honey + 100µl of glucose oxidase stock (100U/ml)
- B- 6U/g (6U/ml) referred to as 'High' – 5g honey + 300µl of glucose oxidase stock (300U/ml)

20 30µl of each was added to a disc/biofilm.

The assay plates were parafilmed and incubated for 24 hours at 37 °C with 80rpm shaking to allow biofilm disruption. Unused wells were filled with PBS to increase humidity and prevent evaporation.

25 After incubation (with shaking) at 37 degrees, discs/biofilms were removed and placed in 665 µL DE neutralising broth (1:20 dilution) for 10 mins, vortexed vigorously for 3 minutes then subjected to serial dilution and viable counting onto TSA by Miles and Misra (1:10 serial dilutions, 10µl spots in triplicate onto agar).

Results

Both the compositions comprising honey and glucose oxidase demonstrated significant inhibition of 24 hour old single species biofilms of *P. aeruginosa* and *S. aureus*, whereas compositions comprising honey alone and glucose oxidase alone showed no inhibition of 5 the biofilm. Prontosan® gel was highly active against *S. aureus* biofilms but had less activity against *P. aeruginosa* biofilms (see Figures 1 and 2).

Claims

1. A composition comprising an oxidoreductase enzyme and a substrate for the enzyme for use in a method of treating or preventing biofilm formation by a population of pathogenic bacteria, the method comprising administering the composition to a patient.
2. The composition of claim 2, wherein the oxidoreductase enzyme is glucose oxidase and the substrate is glucose.
3. The composition of claim 1 or claim 2, wherein the population of pathogenic bacteria comprises *Pseudomonas aeruginosa*, *Staphylococcus aureus* and/or *Staphylococcus epidermidis*.
4. The composition of any one of claim 1 to 3, wherein the population of pathogenic bacteria comprises *Pseudomonas aeruginosa*.
5. The composition of any preceding claim, wherein the composition does not comprise lactoperoxidase.
6. The composition of any preceding claim, wherein the composition consists of the enzyme, substrate and a pharmaceutically acceptable carrier.
7. A wound dressing for use in treating or preventing biofilm formation by a population of pathogenic bacteria, wherein the wound dressing comprises a composition as defined in any one of claims 1-6.
8. A method of preventing formation of a pathogenic bacterial biofilm on a surface or of removing a pathogenic bacterial biofilm from a surface, comprising administering a composition comprising an oxidoreductase enzyme and a substrate for the enzyme to said surface.
9. A method according to claim 8, which is performed *ex vivo* or *in vitro*.
10. A method according to claim 8, which is performed *in vivo*.
11. A method for the treatment or prevention of biofilm formation on a surface by a population of pathogenic bacteria, comprising administration of a therapeutic amount of a composition comprising an oxidoreductase enzyme and a substrate to the surface.

12. A method for the treatment or prevention of biofilm formation by a population of pathogenic bacteria, comprising administration of a therapeutic amount of a composition comprising an oxidoreductase enzyme and a substrate to a patient in need thereof.
13. The method of any of claims 8 to 12, wherein the oxidoreductase enzyme is glucose oxidase and the substrate is glucose.
14. The method of any one of claims 8-13, wherein the population of pathogenic bacteria comprises *Pseudomonas aeruginosa*, *Staphylococcus aureus* and/or *Staphylococcus epidermidis*.
15. The method of any one of claim 8 to 14, wherein the population of pathogenic bacteria comprises *Pseudomonas aeruginosa*.
16. The method of any one of claims 8 to 15, wherein the composition does not comprise lactoperoxidase.
17. The method of any one of claims 8-16, wherein the composition consists of the enzyme, substrate and a pharmaceutically acceptable carrier.
18. The method of any one of claims 12-17, wherein the composition is administered to a wound on the patient.
19. A method for the treatment or prevention of biofilm formation by a population of pathogenic bacteria, comprising administration of a therapeutic amount of a composition consisting of an oxidoreductase enzyme, a substrate for the enzyme and a pharmaceutically acceptable carrier to a patient in need thereof.
20. A method of treating a wound to treat or prevent biofilm formation by a population of pathogenic bacteria, the method comprising administering a composition comprising an oxidoreductase enzyme, a substrate for the enzyme, and optionally a pharmaceutically acceptable carrier to the site of the wound.
21. A method according to claim 20, comprising applying a wound dressing incorporating the composition.
22. A method according to claim 21, wherein the wound dressing comprises a foam or gauze comprising the composition.

23. A method according to any of claims 20 to 22, wherein the enzyme and substrate are administered as separate components, optionally in separate layers of a wound dressing.
24. A method according to any of claims 20 to 23, comprising a preceding step of identifying a wound containing, or at risk of infection by, a population of biofilm-forming pathogenic bacteria.
25. A method according to any of claims 20 to 24, wherein the wound is a chronic wound.
26. A method according to any of claims 20 to 25, wherein the method of treating the wound further comprises negative pressure therapy.
27. A method, composition or use substantially as described herein.




FIGURE 1




FIGURE 2